Rethinking HEOR Market Access Integration: A Ca...

By João L. Carapinha

November 24, 2025

Early HEOR Market Access Integration In this brief interview on ISPOR, Indranil Bagchi asserts that HEOR market access integration must o...
NICE NHS Prioritization: A Strategic Shift to Address Healthcare Challenges
NICE Endorses Darolutamide Prostate Cancer Treatment for Improved Patient Access
Paving the Way for Digital Health Technologies: NICE’s Bold New Strateg...
NICE Kidney Cancer Guideline: Enhancing Biopsy Use to Minimize Unnecessary Su...
NICE Endorses Breakthrough Bladder Cancer Treatment for Enhanced Survival
Assessment of Glofitamab With Gemcitabine in DLBCL Reveals No Additional Benefit
Key Decisions on Health Technology Assessment at ACP124: Implications for Rar...
Rare Medications Coverage in the Netherlands: Price Reductions Required
NICE’s 2025 Guidance on Obesity Management Support
NICE HealthTech Methods Update
Navigating Challenges for Small Countries to Access Innovative Medicines
Model Type and Its Impact on Pneumococcal Vaccine Cost-Effectiveness in Germany